Mr. Graves is a global industry leader with more than 20 years of U.S. and global general management experience in top-tier U.S. and Europe-based pharmaceutical and biotechnology companies, including Merck, Novartis, and Vertex. He has successfully built and managed several of the largest multibillion-dollar franchises in the industry and developed and launched 12 blockbuster brands in a broad range of general medicine, specialty, and orphan disease areas. In addition to driving dynamic top- and bottom-line growth in large global pharmaceutical companies, Mr. Graves also played a key leadership role in building two highly successful early-stage companies: Astra Merck Pharmaceuticals and Vertex Pharmaceuticals. Mr. Graves is currently the Chairman, President, and CEO of Intarcia Therapeutics. Prior to that, he served as Executive Vice President, Head of Corporate and Strategic Development, and Chief Commercial Officer at Vertex Pharmaceuticals. Prior to his tenure at Vertex, Mr. Graves spent nearly 10 years at Novartis Pharmaceuticals, most recently as Global Head of the General Medicines Business Unit and Chief Marketing Officer for the Pharmaceuticals division. Prior to his tenure at Novartis, Mr. Graves held several commercial and general management positions at Merck and Astra Merck Pharmaceuticals, where he spent most of his time leading the GI Business Unit responsible for Prilosec and Nexium. Mr. Graves is Chairman of the Board at Intarcia and at Radius Health and serves as a Director at Achillion and Pulmatrix. He holds a BS in Biology from Hillsdale College and has attended numerous executive leadership programs at Harvard, the Wharton School, and the University of Michigan.
Mr. Auerbach is the Founder, President, and CEO of Puma Biotechnology, a company dedicated to in-licensing and developing drugs for the treatment of cancer. Previously, he founded Cougar Biotechnology and served as the company's President and CEO until the company's acquisition by Johnson & Johnson in 2009. Following the acquisition, Mr. Auerbach served as the Co-Chairman of the Integration Steering Committee at Cougar that provided leadership and oversight for the development and global commercialization of Cougar's lead product candidate, abiraterone acetate, for the treatment of advanced prostate cancer. Prior to founding Cougar, Mr. Auerbach was a Vice President, Senior Research Analyst at Wells Fargo Securities, where he was responsible for research coverage of small- and middle- capitalization biotechnology companies, with a focus on oncology. He had primary responsibility for technical, scientific, and clinical due diligence as well as selection of biotechnology companies followed by the company. Prior to that, Mr. Auerbach was a Vice President, Research Analyst at the Seidler Companies, where he was responsible for research coverage of small-capitalization biotechnology companies. Previous to his work as a biotechnology analyst, Mr. Auerbach worked for Diagnostic Products Corporation, where he designed and implemented clinical trials in the field of oncology. Mr. Auerbach received a BS in Biomedical Engineering from Boston University and an MS in Biomedical Engineering from the University of Southern California.
Dr. Gadicke is a Co-Founder and Managing Director of MPM Capital. He led MPM's effort to build its Advisory and Investment Banking business from 1992 to 1996 and started its Asset Management business in 1996. Prior to founding MPM, Dr. Gadicke was employed by The Boston Consulting Group. He received an MD from J.W. Goethe University in Frankfurt and subsequently held research positions in Biochemistry and Molecular Biology at the Whitehead Institute at MIT, Harvard University, and the German Cancer Research Center. He has published in leading scientific publications, including Nature and Cell. Dr. Gadicke is also a Director of Cerimon Pharmaceuticals; Dragonfly Sciences; SolasiaPharma K.K., Tokyo; and Verastem. He previously served as a Director of Arriva Pharmaceuticals, BioMarin, Biovitrum, Chiasma, Coelacanth, Idenix, Kourion, MediGene, Omrix Biopharmaceuticals, Pharmasset, PharmAthene, Transform, Xanodyne Pharmaceuticals, and ViaCell. He is a member of the Board of Fellows of Harvard Medical School.
Dr. Münchbach is Managing Director of BB Biotech Ventures. Previously, he was Partner at BioMedinvest and Investment Advisor at HBM Partners. At BioMedinvest, he led several of the firm's investments and served on the board of portfolio companies. Before the merger of HBM Bioventures and NMT New Medical Technologies, he was Investment Manager at NMT, where he focused on international private equity investments in biopharmaceutical and biotechnology companies. Prior to his investment career, Dr. Münchbach gained experience in strategic marketing at Sanofi-Synthelabo. Dr. Münchbach also serves as a director of BioVascular, Molecular Partners AG, Optimer Pharmaceuticals, and Tioga Pharmaceuticals, Inc. He holds a PhD in Protein Chemistry, an MSc in Biochemistry, and a Master in Industrial Engineering and Management from the Swiss Federal Institute of Technology (ETH), Zurich.
Dr. Stoner is a Managing Director at MPM Capital. An industry veteran with broad expertise in clinical research and pharmaceutical product development, Dr. Stoner joined MPM following a 22-year career at Merck Research Laboratories, where she served most recently as a Senior Vice President of Global Clinical Development Operations, with responsibility for Merck's clinical development activities in more than 40 countries. Dr. Stoner also oversaw the clinical development activities of Merck's Japanese partner, Banyu, led clinical development for the Merck/Schering-Plough Joint Venture for Zetia/Vytorin, and played a critical leadership role in Merck's efforts to transform its worldwide clinical development operations. Earlier in her career at Merck, she led the Proscar clinical development program from inception to establishing Merck as a leader in the field of prostate disease. As the Endocrine Therapeutic Head, Dr. Stoner's responsibilities included steroid and lipid metabolism, as well as the growth hormone secretagogue clinical research programs. Prior to her tenure at Merck, Dr. Stoner served as an Assistant Professor of Pediatrics at Cornell University Medical College. Dr. Stoner also serves as a director for Momenta Pharmaceuticals and is a member of the Scientific Advisory Board at Solasia. She received an MD from Albert Einstein College of Medicine, an MS in Chemistry from the State University of New York at Stony Brook, and a BS in Chemistry from Ottawa University, Kansas.
Mr. Wyzga is President and Chief Executive Officer, and a member of the Board of Directors, of Radius. Prior to joining Radius, he was Executive Vice President, Finance and Chief Financial Officer of Genzyme until its acquisition by Sanofi in April 2011. Mr. Wyzga joined Genzyme in 1998 and held primary responsibility for the firm's financial management worldwide. He provided strategic leadership in the successful $20.1 billion sale of Genzyme to Sanofi, the second-largest acquisition in biotechnology history. Prior to joining Genzyme, Mr. Wyzga was Chief Financial Officer of Sovereign Hill Software. He previously served as Vice President of Finance and Chief Financial Officer of CacheLink Corporation, a client/service software company. Mr. Wyzga also held management positions at Lotus Development Corporation and Digital Equipment Corporation. He received an MBA from Providence College and a BS from Suffolk University.
Mr. Hughes serves as the Chief Business Officer and Head of Corporate Development at Intarcia Therapeutics, Inc. Prior to Intarcia, he served as a Director at Brookside Capital, a multi-billion dollar hedge fund under the Bain Capital umbrella, managing public and private healthcare investments. Owen has 16 years of investing experience on both the buy and sell side, including positions at Pyramis Global Advisors, Triathlon Fund Management, Ziff Brothers Investments and Morgan Stanley/Merrill Lynch. He earned a bachelor of arts from Dartmouth College, held All-Ivy Honors, Academic All-Ivy Honors and was a four-year letterman on the varsity ice hockey team.
Dr Jovan-Embiricos has extensive experience, both within the public and private equity markets. In 2003 Dr. Jovan-Embiricos launched F2 Ventures, a biotech venture capital fund, followed by F3 Ventures in 2010. Prior to launching F3 Ventures, she successfully managed a biotech allocation for one of the largest hedge funds in the USA. In parallel, she was a Venture Partner with MPM Capital until March 2004, which at the time was the largest biotech venture capital firm worldwide. In addition to being on the investment side, she also worked closely with portfolio companies in attaining critical business development milestones and securing appropriate exits either through trade sale or an IPO. She joined MPM in 2000 from Banque Syz & Co in Geneva, where she led the Bank’s activities in Life Sciences investments. She was also a part of the newly established Alternative Investments team and was responsible for new product structuring. She launched one of the first long-only biotech funds in Switzerland. Dr. Jovan-Embiricos holds an Executive MBA from Stanford-National University of Singapore and was a Post-Doctoral Fellow at Harvard University having worked on Protein Un-caging in the Department of Developmental Biology. She received her PhD in Biophysical Chemistry from the University of Cambridge. Dr Jovan-Embiricos has published numerous articles on the Biotechnology sector for leading European financial journals, and sits on the Board of private and public life science companies.